A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Keller, Marla J ^a   Madan, Rebecca P ^a   Merna Torres, N ^a   Fazzari, Melissa J ^a   Cho, Sylvia ^a   Kalyoussef, Sabah ^a   Shust, Gail ^a   Mesquita, Pedro M M ^a   Louissaint, Nicolette ^b   Chen, Jianmeng ^b   Cohen, Hillel W ^a   Diament, Erin C ^a   Lee, Anna C ^a   Soto Torres, Lydia ^c   Hendrix, Craig W ^b   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; BIOLOGICAL MARKER; ESTRADIOL; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; LUCIFERASE; LYSOZYME; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; PLACEBO; PROGESTERONE; PROTEIN; RANTES; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TENOFOVIR; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TISSUE LEVEL; ESCHERICHIA COLI; FEMALE; GEL; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; MUCOSAL IMMUNITY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SPERM; UTERINE CERVIX MUCUS; VAGINAL LAVAGE; VAGINAL PRURITUS; VULVA PRURITUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOXICITY; FEMALE GENITAL SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MUCOSA; SECRETION;

HUMAN HERPESVIRUS 2;

ADENINE; ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; MUCOUS MEMBRANE; PHOSPHONIC ACIDS; SEMEN; VAGINAL DOUCHING; YOUNG ADULT;

EID: 79551565205     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016475     Document Type: Article

References (32)

1. Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, et al. (2006) PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 193: 27-35.
2. Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, et al. (2007) PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. Aids 21: 467-476.
3. Patel S, Hazrati E, Cheshenko N, Galen B, Yang H, et al. (2007) Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis 196: 1394-1402.
4. Keller MJ, Mesquita PM, Torres NM, Cho S, Shust G, et al. (2010) Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One 5: e8781.
5. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, et al. (2010) In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 5: e9310.
6. Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, et al. (2009) Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 83: 10358-10365.
7. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, et al. (2008) Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 5: e157; discussion e157.
8. Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, et al. (2009) Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 200: 599-608.
9. Wilson SS, Cheshenko N, Fakioglu E, Mesquita PM, Keller MJ, et al. (2009) Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir Ther 14: 1113-1124.
10. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, et al. (2006) Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 20: 543-551.
11. Hillier SL, Justman J, Joshi S, Hoesley C, Cyrus-Cameron E, et al. Safety and acceptability of coitally dependent use of 1% tenofovir gel over six months of use 2008 February 25; New Delhi, India).
12. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
13. Delaney WE, Ray AS, Yang H, Qi X, Xiong S, et al. (2006) Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 50: 2471-2477.
14. Garcia-Lerma G, Cong ME, Zheng Q, Holder A, Martin A, et al. Efficacy of intermittent prophylaxis with tenofovir and emtrictabine against rectal SHIV transmission in macaques and relationship to systemic and mucosal drug levels; 2010; San FranciscoCA).
15. Haase AT (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464: 217-223.
16. Valore EV, Park CH, Igreti SL, Ganz T (2002) Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 187: 561-568.
17. Hein M, Valore EV, Helmig RB, Uldbjerg N, Ganz T (2002) Antimicrobial factors in the cervical mucus plug. Am J Obstet Gynecol 187: 137-144.
18. John M, Keller MJ, Fam EH, Cheshenko N, Hogarty K, et al. (2005) Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 192: 1731-1740.
19. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM (2005) Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 175: 7560-7567.
20. Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, et al. (2009) Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. Aids 23: 309-317.
21. Shust GF, Cho S, Kim M, Madan RP, Guzman EM, et al. (2009) Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol 63: 110-119.
22. (2004) The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1, December 2004. Available at: http://rsc.tech-res.com/safetyandpharmacovigilance. Accessed December 22, 2010.
23. Herold BC, Siston A, Bremer J, Kirkpatrick R, Wilbanks G, et al. (1997) Sulfated carbohydrate compounds prevent microbial adherence by sexually transmitted disease pathogens. Antimicrob Agents Chemother 41: 2776-2780.
24. King T, Bushman L, Anderson PL, Delahunty T, Ray M, et al. (2006) Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology. J Chromatogr B Analyt Technol Biomed Life Sci 831: 248-257.
25. Wallace AR, Teitelbaum A, Wan L, Mulima MG, Guichard L, et al. (2007) Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception 76: 53-56.
26. Austin MN, Rabe LK, Hillier SL (2009) Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis 36: 368-371.
27. Ghosh M, Fahey JV, Shen Z, Lahey T, Cu-Uvin S, et al. (2010) Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One 5: e11366.
28. Hawkins T, Veikley W, St Claire RL, 3rd, Guyer B, Clark N, et al. (2005) Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 39: 406-411.
29. Pruvost A, Negredo E, Theodoro F, Puig J, Levi M, et al. (2009) Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavirritonavir. Antimicrob Agents Chemother 53: 1937-1943.
30. Wallace A, Thorn M, Maguire RA, Sudol KM, Phillips DM (2004) Assay for establishing whether microbicide applicators have been exposed to the vagina. Sex Transm Dis 31: 465-468.
31. Hogarty K, Kasowitz A, Herold BC, Keller MJ (2007) Assessment of adherence to product dosing in a pilot microbicide study. Sex Transm Dis 34: 1000-1003.
32. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, et al. (2009) Glycerol monolaurate prevents mucosal SIV transmission. Nature 458: 1034-1038.